Low treatment related mortality and improved survival in allogeneic peripheral blood stem cell transplant: Targeted intravenous Busulfan combined with Fludarabine (tBuFlu) as conditioning regimen

Myeloablative doses of intravenous busulfan in combination with fludarabine have been employed as conditioning before hematopoietic cell allografts with reduced treatment-related toxicity and mortality. In this report, we describe the early results of a targeted busulfan pharmacokinetic dosing strategy (tBuFlu) used in combination with fludarabine before either related or unrelated grafts We treated 61 pts with tBuFlu prior to allogeneic peripheral blood stem cell transplantation. The median patient age was 48 (range 22-68) years.